Clinical Observation Of Tongxinluo In The Treatment Of Angina Pectoris (Qi Deficiency And Blood Stasis Type) Associated With Anxiety And Depression In Coronary Heart Disease

Purpose: To observe the clinical efficacy and safety of Tongxinluo in treating angina pectoris of coronary heart disease(Qi deficiency and blood stasis type)with anxiety and depression,so as to provide more clinical ideas for Tongxinluo in treating angina pectoris of coronary heart disease with anxiety and depression.Material and method:80 patients with stable angina pectoris with anxiety and depression and Qi deficiency and blood stasis type diagnosed and measured by menstrual scale in department K of Cardiology,Affiliated Hospital of Liaoning University of traditional Chinese medicine from January 2019 to October 2020 were randomly divided into two groups,40 cases in the control group were given conventional Western Medicine for the treatment of coronary heart disease angina pectoris;40 cases in the experimental group were treated with Tongxinluo capsule in addition to conventional western medicine.The observation course of the two groups was set at 5 weeks.The indexes of angina pectoris curative effect,TCM syndrome curative effect,GAD-7,PHQ-9,PSQI and safety monitoring indexes of the control group and the experimental group were observed before and after treatment.All data were analyzed by SPSS 23.0.Result:1.Angina pectoris indicators: after treatment,the angina pectoris indicators of the two groups were lower than before treatment(p < 0.01),the total effective rates of the control group and the experimental group were 80% and 90% respectively,and the curative effect of the experimental group was significantly better than that of the control group(p < 0.05).2.TCM syndrome indicators: after treatment,the TCM syndrome indicators of the two groups were lower than before treatment(p< 0.01).The total effective rates of the control group and the experimental group were 83% and 92% respectively.The curative effect of the experimental group was significantly better than that of the control group(p< 0.05).3.GAD-7 index: after treatment,the anxiety indexes of the two groups were lower than before treatment(p< 0.01),and the experimental group was better than the control group in improving the degree of anxiety(p< 0.05).4.PHQ-9 index: after treatment,the depression indexes of the two groups were lower than before treatment(p< 0.01),and the experimental group was better than the control group in improving the degree of depression(p< 0.05).5.PSQI index: after treatment,the sleep quality indexes of the two groups were lower than before treatment(p< 0.01),and the experimental group was better than the control group in improving sleep quality(p< 0.05).6.Safety indicators: there were no adverse reactions in this study,no aggravation of symptoms in patients,no serious adverse reactions or side effects in this trial,and no obvious abnormality in safety indicators monitoring,so the treatment schemes of the two groups were safe.Conclusion: Tongxinluo can reduce the anxiety and depression scores of patients with angina pectoris and anxiety and depression,improve sleep quality,relieve TCM discomfort syndrome and relieve angina pectoris symptoms.Blood,urine,stool routine,liver and kidney function test indicators are normal,clinical use is safe.